Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. is seeking to list on the Hong Kong Stock Exchange after previously withdrawing its A-share IPO application, citing the need for international expansion and a more accommodating market for profit fluctuations [1][5]. Financial Performance - The company has shown steady revenue growth but significant profit volatility over the past three years, with revenues of approximately 614.2 million RMB in 2023, 654.5 million RMB in 2024, and 538.0 million RMB in the first nine months of 2025. Net profits were 92.0 million RMB, 26.4 million RMB, and 113.0 million RMB respectively [2][4]. - In 2024, revenue increased by 6.56% year-on-year, but profits dropped by 70% due to a rise in share-based payment expenses and increased sales and administrative costs [2][4]. Business Model and Market Position - Shanghai Shengsheng is a provider of integrated temperature-controlled supply chain services in the pharmaceutical and life sciences sector, focusing on clinical trial temperature control services, which account for over 82% of its revenue [6][10]. - The company is the largest domestic provider of clinical trial temperature-controlled supply chain services and ranks among the top ten globally, serving over 7,000 clients and supporting more than 4400 new drug clinical trial applications [10]. Growth Opportunities - The company plans to use IPO proceeds to expand its operations both domestically and internationally, including the establishment of new regional operational centers and clinical drug warehouses [11]. - The innovative drug sector is experiencing high growth, with a record number of new drug approvals and significant market activity, which may benefit Shanghai Shengsheng's business [8]. Challenges - The company faces high customer concentration, with the top five clients accounting for an increasing percentage of sales, which poses a risk if key client relationships change [5]. - Trade receivables have been growing, indicating potential cash flow pressures, with the turnover days extending from 98 to 105 days [5]. - The company is also exploring new applications for its temperature control technology in advanced manufacturing and renewable energy sectors, but these markets present different challenges and may not yield immediate results [12]. Conclusion - While Shanghai Shengsheng is well-positioned in a growing industry with a solid business model, it must navigate significant operational challenges and market competition to achieve sustainable growth and develop new revenue streams [13].

Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, facing scrutiny over internal control issues despite its industry advantages and market position [1] Group 1: Company Overview - Shanghai Shengsheng is a leading integrated temperature-controlled supply chain service provider in the pharmaceutical and life sciences sector, focusing on clinical trial temperature-controlled supply chain services [2] - The company achieved revenues of 614 million yuan, 654 million yuan, and 538 million yuan for the years 2023, 2024, and the first three quarters of 2025, respectively, with profits of 92.03 million yuan, 26.396 million yuan, and 113 million yuan during the same periods [2] - The revenue structure is primarily derived from clinical trial temperature-controlled supply chain services, which consistently account for over 80% of total revenue [2] Group 2: Market Dynamics - The growth in Shanghai Shengsheng's performance is driven by the expanding market size and technological demands, with the clinical trial temperature-controlled service market in China growing from 2 billion yuan in 2020 to 3.6 billion yuan in 2024 [3] - The company holds both GMP and GDP certifications, establishing a nationwide service network to meet the stringent temperature control and safety requirements of the pharmaceutical industry [3] Group 3: Financial Performance and Challenges - The accounts receivable of Shanghai Shengsheng increased significantly, with trade receivables of 157 million yuan, 192 million yuan, and 220 million yuan during the reporting period, and the turnover days for trade receivables were 98 days, 98 days, and 105 days, respectively [4] - The company acknowledged that some transactions with clients are settled on credit, which could adversely affect its cash flow and business operations if clients fail to pay on time [4] Group 4: Governance Issues - Concerns regarding internal control governance arose when the actual controllers borrowed funds to increase their shareholding and subsequently transferred shares at a premium, raising regulatory scrutiny [5] - The significant difference in share transfer prices has led to questions from regulators, although the company has stated that there are reasonable backgrounds for these price variations [5] - In 2024, the company reported a substantial drop in profits primarily due to share-based payment expenses amounting to 72.12 million yuan, with a significant portion of these expenses attributed to a few high-salaried employees [6]

Core Viewpoint - Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, seeking to expand its business internationally after previously withdrawing its A-share IPO application [1][2][3]. Company Overview - Established in 2009, Shanghai Shengsheng focuses on temperature-controlled supply chain services for clinical trials and is the leading provider in China and one of the top ten globally [4]. - The company reported revenues of approximately 614.19 million RMB, 654.49 million RMB, and 538.71 million RMB for the fiscal years 2023, 2024, and the first three quarters of 2025, respectively [5]. Financial Performance - For the fiscal year 2023, the company achieved a profit of 92.03 million RMB, which is expected to decline by 70% in 2024 [5]. - The sales and marketing expenses increased by 56.8%, administrative expenses rose by 96.1%, and R&D expenses grew by 4.6% in 2024 compared to the previous year [5]. Trade Receivables - The company has highlighted potential adverse impacts on its financial performance due to the recoverability of trade receivables, which amounted to approximately 158 million RMB, 192 million RMB, and 221 million RMB at the end of the reporting periods [6]. - The average collection period for trade receivables was 98 days for 2023 and 2024, increasing to 105 days in 2025 [6]. Shareholding Structure - The chairman, Ju Jibing, controls approximately 42.62% of the voting rights in the company, with his family and associated entities forming the controlling shareholder group [6]. Related Party Transactions - Ju Jibing and his spouse have previously engaged in significant borrowing from the company for equity acquisitions, totaling 74.66 million RMB [7][8]. - Notably, the couple's entity, Ningbo Yanjia, has been involved in both borrowing funds from the company and selling shares for cash [9].

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Shanghai Shengsheng Pharmaceutical Cold Chain Technology Co., Ltd.* 上海生生醫藥冷鏈科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供資料予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、本公司的聯席保薦人、整體協調人、聯席全球協調人、顧問或包銷團成員表示 同意： 倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長註冊的本公 司招股章程作出投資決定；該文件的文本將於發售期內供公眾人士查閱。 * 僅供識別 (a) 本文件僅為向香港公眾人士提供有關本公司的資 ...